Fig. 1From: Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidenceParticipants flow chart. GLA glucose lowering agent; SGLT2i Sodium/glucose cotransporter-2 inhibitors; ESKD end stage kidney disease; MHS Maccabi Health Systems; T1D type 1 diabetes; eGFR estimated glomerular filtration rateBack to article page